Pooja Mathur

Pooja Mathur

Auto-generated profile, based on publicly available information

Pooja Mathur

Department of Pharmacy, School of Healthcare and Allied Sciences, G.D. Goenka University, Gurugram, 122103, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Recent Advances in Inflammation & Allergy Drug Discovery
Verified
Journal Article
Closed access
PDF file
MMMohd Monis
Mohd Monis
PMPooja Mathur
Pooja Mathur
RIRitu
Ritu
AMAshwini Kumar Mishra
Ashwini Kumar Mishra
LRLaxmi Rani
Laxmi Rani
Psoriasis, a chronic inflammatory skin disorder affecting approximately 2% of the global population, is characterized by a complex interplay of immunological dysregulation, genetic predisposition, and environmental factors. This review explores the dynamic mechanisms underlying psoriasis, highlighting the role of T lymphocytes in targeting healthy skin cells, leading to inflammation and the formation of characteristic white scaly patches on various body parts. Over the past 15 years, significant strides in unraveling the origins of psoriasis have paved the way for the development of precise and highly effective treatments. Key insights into the pathogenesis, particularly the dominance of interleukin-17 (IL-17) and interleukin-23 (IL-23), have shaped therapeutic strategies to mitigate chronic inflammatory disorders. Notably, various therapies employing different mechanisms of action, including interleukin blockers and tumor necrosis factor-alpha (TNF- α) inhibitors, have emerged as valuable options for psoriasis management. This review provides a comprehensive overview of the current understanding of psoriasis pathophysiology and highlights advanced therapeutic approaches that are widely accessible. The focus extends to emerging targeted drugs, such as netakimab, which functions as an interleukin-17 blocker, currently undergoing clinical trials for psoriasis treatment. By synthesizing the latest research findings, this article aims to contribute to the knowledge base surrounding psoriasis, offering clinicians and researchers valuable insights into the evolving landscape of psoriasis treatment modalities.

1 March 2023 in Drug Delivery Letters
Verified
Journal Article
Closed access
PDF file
PMPooja Mathur
Pooja Mathur
RVRavinder Verma
Ravinder Verma
MKManish Kumar
Manish Kumar
VJVikas Jhawat
Vikas Jhawat
RDRohit Dutt
Rohit Dutt
SBShailendra Bahtt
Shailendra Bahtt
Rheumatoid arthritis (RA) is a well-known chronic inflammatory disease that results in articular degradation, comorbidities, and body part functional loss. In the last two decades, the development of effective biologics and small compounds, such as Janus kinase inhibitors (Jakinibs), has significantly improved clinical outcomes. Low-molecular-weight chemicals known as jakinibs are currently used for effective treatment of RA. Jakinibs are a new class of drugs being developed to treat RA, and several of them are now in different phases of clinical trials to establish their safety and efficacy in humans. Jakinibs can be very different in their selectivity against JAK inhibitors. For an efficient therapy of RA, it is critical to fully comprehend the properties of JAK inhibitors as well as their mechanism of action. Tofacitinib, Baricitinib, Upadacitinib, Peficitinib, Filgotinib, Decernotinib, Itacitinib, Ruxolitinib, and PF-06651600 are a few selective orally active Jakinibs that have entered clinical trials to treat RA. This review aims to elaborate on Jakinibs for the treatment of Rheumatoid Arthritis (RH), including their mechanism of action (MOA), efficacy and safety profiles, clinical trials of adverse effects (AEs) associated with Jakinibs and combination therapy with other DMARDs.

22 October 2025 in Recent Advances in Anti-Infective Drug Discovery
Verified
Journal Article
Closed access
PDF file
KQKhushi Quadri
Khushi Quadri
LRLaxmi Rani
Laxmi Rani
PMPooja Mathur
Pooja Mathur
Bacterial conjunctivitis is a common eye infection caused by bacteria, posing significant treatment challenges due to rising antibiotic resistance and the limitations of traditional therapies. Standard treatments, including topical antibiotics, often suffer from issues such as poor bioavailability, limited effectiveness, and patient adherence. Nanotechnology offers an innovative approach, providing potential solutions for more effective drug delivery, diagnostics, and therapeutic interventions. The objective of this study is to explore the role of nanotechnology in improving the management of bacterial conjunctivitis. Specifically, it examines how nanostructured drug carriers, such as nanoparticles, nanogels, and liposomes, can enhance ocular drug delivery and therapeutic outcomes. A key focus is on the influence of the hydrodynamic radius (Rh) in optimizing stability, solubility, and bioavailability. Nanotechnology has shown promise in improving the delivery of drugs for bacterial conjunctivitis by enhancing ocular penetration and prolonging the release of active agents. The hydrodynamic radius (Rh) of nanoparticles plays a critical role in stabilizing the colloidal structure of the formulation, preventing aggregation and sedimentation. Furthermore, optimizing Rh can increase the surface area-to-volume ratio, which is beneficial for improving the solubility of poorly soluble drugs, thereby enhancing their bioavailability. Nanotechnology- based systems can also enable the development of diagnostic tools, such as nanosensors, capable of quickly and accurately detecting bacterial pathogens, facilitating timely, targeted treatments and reducing unnecessary use of broad-spectrum antibiotics. The precise control of nanoparticle Rh enhances drug stability, bioavailability, and sustained release, ultimately improving patient compliance and therapeutic efficacy. The future of bacterial conjunctivitis treatment is promising, with further research focused on optimizing nanoparticle characteristics such as size, surface modification, and targeted drug delivery. However, challenges remain, particularly concerning the safety of nanoparticles, including potential risks to ocular tissues and long-term effects. Continued research, including in vitro and in vivo studies as well as clinical trials, is essential to establish the safety and clinical viability of these nanotechnology-based systems. With further advancements, nanotechnology could revolutionize treatment strategies for bacterial conjunctivitis, offering more targeted, patient-centered, and effective solutions for managing ocular infections and combating antibiotic resistance.

29 May 2025
Verified
Book
Closed access
RDRitu Dahiya
Ritu Dahiya
PMPooja Mathur
Pooja Mathur
LRLaxmi Rani
Laxmi Rani
ASAjay Pal Singh
Ajay Pal Singh